Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Noven Pharmaceuticals (NOVN) -- Ignore unavailable to you. Want to Upgrade?

To: zizzerzazzer who wrote (50)	8/10/1999 12:44:00 PM
From: zizzerzazzer	Read Replies (1) \| Respond to of 66

Fahnestock Earnings Upgrade: Fahnestock raised its 1999 EPS estimate for Noven form $0.12 to $0.18 due to CombiPatch and the Vivelle Family, and manufacturing efficiency. CompiPatch is experiencing strong growth with weekly prescriptions running at five times the level of 2,025 during the first week of December, 1998. Vivelle-dot's new prescriptions have already added 2% to the Vivelle Family market share which stood at 15.5% before the launch of the dot. Vivelle-dot's small scale is an easily recognizable advantage among estradiol patches and the absence of ethanol reduces skin sensitivity. Management has tuned manufacturing operations to enhance profitability as more patches are manufactured. Noven's facilities have a capacity of 500 million pathces per year. Consequently, Fahnestock forecasts steadily improving gross margins over the next several years. Patience should be rewarded.